Study Details

Back to Search Results

A Study of ASP1570 taken by itself or with pembrolizumab in adults with advanced solid tumors

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05083481

Astellas Study ID

The unique identification code given by the study sponsor.

1570-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

ASP1570

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Oct 2021 - Apr 2027

Masking

None (Open Label)

Enrollment number

266

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumors

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1570 taken by itself or with pembrolizumab in adults with advanced solid tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Nebraska Methodist Hospital

Omaha, United States, 68130

Recruiting
Contact Us

Mary Crowley Research Center

Dallas, United States, 75230

Recruiting
Contact Us

Providence Medical Foundation

Fullerton, United States, 92835

Recruiting
Contact Us

Tennessee Oncology

Nashville, United States, 37203

Recruiting
Contact Us

Florida Cancer Specialist & Research Institute Sarasota

Sarasota, United States, 34232

Recruiting
Contact Us

University Hospitals Cleveland Medical Center

Cleveland, United States, 44106

Recruiting
Contact Us

UPMC Hillman Cancer Center

Pittsburgh, United States, 15232

Recruiting
Contact Us

University of Chicago

Chicago, United States, 60637

Recruiting
Contact Us

University of Kentucky Medical Center MCC-CRO

Lexington, United States, 40536

Recruiting
Contact Us

USC/Norris Comprehensive Cancer Center

Los Angeles, United States, 90033

Recruiting
Contact Us

University of Kentucky Medical Center MCC-CRO

Nashville, United States, 37203

Recruiting
Contact Us

Cancer Institute Hospital Of JFCR

Koto-ku, Japan

Recruiting
Contact Us

National Cancer Center Hospital

Chuo-ku, Japan

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo